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Evidence that hypoxia markers detect oxygen gradients in liver:
pimonidazole and retrograde perfusion of rat liver
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Summary Nitroimidazole markers of tumour hypoxia bind to normoxic liver and the question has been
raised whether this is due to low oxygen concentration or microregional activity of specialised nitroreductases.
To answer this question, the binding patterns of the 2-nitroimidazole, pimonidazole, were compared following
perfusion of surgically isolated rat livers in anterograde and retrograde directions. Perfusion at low flow rates
in anterograde or retrograde directions can be used intentionally to alter oxygen gradients without altering
enzyme distributions. Perfusion by means of the portal vein (anterograde direction) produced pimonidazole
binding in the pericentral region of liver similar to that observed for pimonidazole binding in vivo. A complete
reversal of this binding pattern occurred when the isolated liver was perfused by way of the central vein
(retrograde direction). In this case, pimonidazole binding occurred in the periportal region. The extent and
intensity of binding in the periportal region during perfusion in the retrograde direction was similar to that in
the pericentral region during perfusion in the anterograde direction. It is concluded that low oxygen
concentration rather than the non-homogeneous distribution of nitroreductase activity is the primary deter-
minant of 2-nitroimidazole binding in liver.
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Nitroimidazoles such as misonidazole bind to hypoxic mam-
malian cells with an oxygen dependence similar to that for
radioresistance. This has led to the use of misonidazole and
related compounds as markers of hypoxic, radiation-resistant
tumour cells. Numerous investigations have established the
usefulness of the approach (Chapman, 1991) but nitro-
imidazoles also bind to some normoxic tissues and Cobb et
al. (1990a,b) have questioned whether hypoxia marker bind-
ing is due to oxygen-dependent processes in all cases. A
possible alternative is that local distributions of specific nitro-
reductase activity produce 2-nitroimidazole binding via
oxygen-independent pathways. In support of this view, P450-
dependent enzymes with expected nitroreductase activity
(Belisario et al., 1990; Cenas et al., 1994) are known to be
located in the pericentral region of liver tissue (review,
Jungerman and Katz, 1989) where 2-nitroimidazoles bind
(Maxwell et al., 1989; Cobb et al., 1990a,b). Furthermore,
average oxygen concentrations of 20-120IM in normal tis-
sues (Jones, 1985; Thurman et al., 1986) might be expected to
strongly inhibit 2-nitroimidazole binding given that the bin-
ding rate decreases sharply at oxygen concentrations above
approximately 14liM as measured by oxygen microelectrodes
(Mueller-Klieser et al., 1991). Nevertheless, there is experi-
mental evidence that 2-nitroimidazole binding in many nor-
mal and tumour tissues is primarily dependent on oxygen
concentration and not on the presence of specialised nit-
roreductases in the tissues. For example, MacManus et al.
(1989) found that lowered tissue oxygen concentrations
created by hypobaric oxygen inhalation increased the levels
of misonidazole binding in mouse liver, kidney, spleen, heart
and tumour tissues. Van Os-Corby et al. (1987) reported that
neither the rates of binding nor the oxygen dependence of
binding of misonidazole to isolated liver tissue was
significantly different from that for brain, heart and tumour
tissues. They also reported that binding rates in isolated
hepatocytes were similar to or lower than those for other
cells, and it was concluded that bioreductive enzymes in
hepatocytes do not confer unique binding properties on these
cells (Van Os-Corby, 1986). Parliament et al. (1992) found
that inhibitors of the oxygen-independent nitroreductase,
NAD(P)H:quinone acceptor oxidoreductase (DT
diaphorase), did not significantly inhibit the in vivo binding
of misonidazole to mouse liver, parotid gland, oesophageal
mucosa or tumour tissue. These results support the idea that
oxygen-dependent processes determine marker binding in
most normal and tumour tissue but they do not prove that
patterns of marker binding in normal tissues are solely due to
regions of low oxygen concentration.
It will be difficult to resolve the relative importance of
microregional nitroreductase activity and local oxygen
gradients in many normal tissues, but current knowledge of
sublobular compartmentation (Thurman and Kauffman,
1985) in conjunction with the perfused liver model (e.g. Ballet
and Thurman, 1991) lays a solid basis for answering the
question in liver. As noted above, nitroimidazole binding in
liver occurs near the central vein which is a region of low
oxygen concentration (Thurman et al., 1986) and high
cytochrome P450-dependent, redox enzyme activity (Junger-
man and Katz, 1989). The question is whether elevated P450-
dependent nitroreductase activity can circumvent oxygen
dependence for nitroimidazole binding and, combined with
oxygen-independent nitroreductases such as DT diaphorase,
weaken the link between tissue P02 and marker binding. One
way to answer this question is to vary P02 gradients while
leaving nitroreductase distribution unchanged. This can be
achieved in isolated livers by perfusion at low-flow rates
whereby regions ofhypoxia can be created intentionally with-
out changing enzyme distributions (Thurman and Kauffman,
1985). For example, perfusion at low flow rates through the
portal vein of liver (anterograde direction) creates hypoxia in
the pericentral regions while perfusion of the organ through
the central vein (retrograde direction) creates hypoxia in the
periportal regions. In order to relate the present study to that
of Cobb et al. (1990b), pimonidazole, along with associated
immunochemical reagents was used as the hypoxia marker.
We have found that perfusion in the retrograde direction
produces a complete reversal of the pericentral binding of
pimonidazole observed when perfusion is in the anterograde
direction. It is concluded, therefore, that P02 is the major
determinant of 2-nitroimidazole-binding patterns in liver.
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Materials and methods
Reagents
Sodium pentobarbitol (Nembutal) was obtained from Aldrich
(Milwaukee, WI, USA). Racemic pimonidazole hydrochlor-
ide was synthesised in our laboratories according to
published procedures (Smithen and Hardy, 1982) and charac-
terised by standard chromatographic, elemental analysis and
spectrographic techniques. Radioactive pimonidazole labelled
with tritium at the 2-position of the sidechain was prepared
in our laboratories by an adaptation of the technique used to
label misonidazole (Born and Smith, 1983). The tritiated
product was shown to have a radiochemical purity greater
than 91% and to co-chromatograph in both thin-layer and
high-performance liquid chromatography systems with auth-
entic pimonidazole. Tanks of analysed gas mixtures used to
test the oxygen dependence of pimonidazole binding to
EMT6 cells were purchased from Matheson Gas Products
(Morrow, GA, USA). Goat serum; goat anti-rabbit IgG
conjugated to alkaline phosphatase; lipid-free, bovine serum
albumin (BSA, product number A-0281); phenylmethylsul-
phonyl fluoride (PMSF) and the chromogenic substrate for
alkaline phosphatase (Sigma 104 phosphatase substrate) were
obtained from Sigma (St Louis, MO, USA). Chemicals used
in the enzyme-linked immunosorbent assay (ELISA) and for
the preparation of formalin-fixed, paraffin-embedded tissue
sections were obtained in reagent grade purity from local
suppliers. Reagents for the BCA protein assay were
purchased from Pierce Chemical (Rockford, IL, USA). Pro-
teinase K was obtained from Life Technologies (Gaithers-
burg, MD, USA) and Brij-35, pronase E, Meyer's haematox-
ylin, crystal mount and buffers used for washing slides during
immunostaining procedures were obtained from Biomeda
(Foster City, CA, USA). Vector Laboratories (Burlingame,
CA, USA) supplied the ABC peroxidase Vectastain kit;
avidin-biotin blocking kit, rat adsorbed horse-antimouse
antibodies; and, DAB peroxidase substrate. Monoclonal
antibody isotyping was carried out with a Clonotyping
System/AP kit purchased from Fisher Scientific (Pittsburgh,
PA, USA).
Polyclonal and monoclonal antibodies
For technical reasons, rabbit polyclonal antibodies were used
for the ELISA (Figures 1 and 2) and a mouse monoclonal
antibody was used for the immunohistochemical studies
(Figures 3 and 4). Polyclonal antisera were used for the
ELISA because they had been calibrated previously. Mono-
clonal antibodies were used for immunohistochemistry
because they were more compatible with the batch-
processing, capillary-action, immunostaining technique used
for the slide-mounted tissue sections (Microprobe, Fisher
Scientific). Competitive ELISA indicated that monoclonal
and polyclonal antibodies recognised the same antigen; i.e.
the sidechain of pimonidazole.
For the preparation of the immunogens for both poly-
clonal and monoclonal antibody production, pimonidazole
was bound to lipid-free, thiolated BSA by means of a radia-
tion chemical reduction described previously (Raleigh and
Koch, 1990). BSA adducts of tritium-labelled pimonidazole
of known specific activity were prepared in a similar manner
and used to calibrate the ELISA. The solid phase antigen for
the ELISA was prepared by radiation chemical reduction of
pimonidazole in the presence of thiolated Ficoll. Thiolated
Ficoll was produced by an adaptation of published proce-
dures (Inman, 1975) with N-succinimidyl 3-(2-pyridyldi-
thio)propionate (Pierce) serving as the source of latent thiol
groups.
The rabbit polyclonal, anti-pimonidazole antisera used in
the calibrated ELISA were prepared and characterised in a
manner analogous to that for CCI-103F - a 2-nitroimidazole
compound with six fluorine atoms on the sidechain (Raleigh
et at., 1987; Cline et al., 1990). The mouse monoclonal
antibody (MAb) to protein-bound pimonidazole was pre-
pared by the North Carolina State University Hybridoma
Facility (Raleigh, NC, USA). The mouse MAb and rabbit
polyclonal antisera were used without further purification.
Isotyping showed the MAb to be IgG, with no detectable
contamination with other immunoglobulins.
Analysis oftissue bound andfree pimonidazole
Competitive ELISA for pimonidazole binding in lysates of
EMT6 cells and in diluted liver homogenates was performed
using the calibrated ELISA based on rabbit polyclonal
antisera in a manner analogous to that used previously for
CCI-103F (Raleigh et al., 1994; Thrall et al., 1994).
Pimonidazole was used as a secondary standard in the
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Figure 1 Competitive ELISA showing the inhibition of anti-
pimonidazole polyclonal antisera binding to a solid phase, Ficoll-
based antigen by selected antigens. The hapten concentrations for
the peptide adducts derived from reductively activated pimonid-
azole bound to BSA (pimo-BSA) were calculated from the
specific activity of the tritium-labelled pimonidazole used to
prepare the BSA adduct. Data points are from a single experi-
ment incorporating replicate ELISA measurements for each
hapten with standard deviations typically ± 5%. A decreasing
rate of chromogen production indicates an increasing inhibition
of antisera binding to the solid phase antigen by the various
soluble antigens: BSA-pimonidazole (d); free pimonidazole (d);
and free hexafluorinated CCI-103F (A). Antigens showing no
cross-reactivity include misonidazole, benznidazole and etanid-
azole (data not shown).
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Figure 2 Oxygen dependence of pimonidazole binding to EMT6
cells measured by ELISA (see Materials and methods).
Pimonidazole binding is presented in terms of nmol bound per
gram of protein in the cell suspensions. Oxygen concentrations
are those in the gas phase over the cells. Data are from two
experiments with overlapping oxygen concentrations. The data
points at 12 p.p.m. (anoxia) and 2 x 05p.p.m. (air) are the
averages of two measurements; the remaining data points are
single measurements.ELISA for which protein-bound [3H]pimonidazole served as
the primary standard (see below).
Weighed samples of rat liver (100 mg) were minced and
suspended in 10 volumes of phosphate-buffered saline/0.05%
Tween (PBS-Tween) solution in a 5 ml round-bottomed
glass tube. The suspension was homogenised for 10 s at the
highest setting in an Omni Mixer fitted with a Minimicro
generator (Omni International, Waterbury, CT, USA). One
aliquot of the homogenate was taken for protein determina-
tion by means of the bicinchoninic acid (BCA) reagent. A
second aliquot was analysed by ultraviolet spectroscopy (UV)
for the presence of unchanged pimonidazole and a third
aliquot was analysed for tissue-bound pimonidazole by
ELISA.
For the UV analysis of unchanged pimonidazole, homo-
genate samples were diluted 1:1 (v/v) with 10% aqueous
trichloroacetic acid (TCA). The suspension was centrifuged
for 10 min at 10000 r.p.m. in an Eppendorf model 5415
Microfuge (Brinkman Instruments, Westbury, NY, USA).
The supernatant was diluted 1:4 in distilled water and
analysed for pimonidazole (324 nm; molar extinction coeffici-
ent = 7810) by means of a Beckman Model DU 70 UV
spectrophotometer (Beckman Instruments, Fullerton, CA,
USA). Unlabelled liver tissue treated in this way showed no
interfering absorption at 324 nm. The limit of detection for
pimonidazole was estimated to be 1 ,iM.
For the ELISA, the homogenates were diluted 1:1 with
PBS-Tween containing 1.0 mg ml-' of proteinase K (20
units mg-') and the mixtures were incubated overnight at
37°C in a shaking water bath. The protease inhibitor, PMSF,
was added to a final concentration of 400 jiM and the mix-
tures were heated for 10 min at 95°C in a hot water bath in
order to completely inactivate the proteinase K. The sample
was centrifuged for 10 min at 10000 r.p.m. in the Eppendorf
Microfuge and aliquots of the supernatant were used for the
ELISA. A goat anti-rabbit secondary antibody conjugated to
alkaline phosphatase combined with a chromogenic substrate
was used to measure the amount of pimonidazole antisera
bound to the solid phase antigen in the ELISA plates.
ELISA values were measured by means of a Molecular
Devices Vmax kinetic plate reader (Molecular Devices, Palo
Alto, CA, USA) in terms of the rate of chromogen formation
(405 nm). The results were analysed by means of Delta Soft
software (BioMetallics, Princeton, NJ, USA) and reported as
milli optical density units per min (milli OD min-', Figure 1).
Oxygen dependence ofpimonidazole binding to mammalian
cells
In order to relate the oxygen dependence of pimonidazole
binding to that published for well studied misonidazole
(Franko et al., 1987), EMT6 cells at 3.1 ± 0.87 x 105
cells ml were suspended in 25 ml of PBS containing 100 jiM
pimonidazole hydrochloride. Cell suspensions were placed in
a series of silanised (Sigmacote; Sigma) glass, 125 ml gas
collection tubes which were thoroughly washed with distilled
water and autoclaved before use. The tubes were mounted on
the deck of an orbital shaker (Model SS110504, Integrated
Separation Systems, Natick, MA, USA) so that cell suspen-
sions could be constantly agitated throughout the gas
exchange and incubation phases of the experiment. Cell
suspensions were equilibrated with gas phases containing 5%
carbon dioxide and varying amounts of oxygen (12 to
2 x 105p.p.m. as analysed by the supplier) in nitrogen. The
equilibration was achieved by means of 15 gas exchanges
under partial vacuum over a period of 10min. Cells were
then incubated in the presence of pimonidazole for 2 h with
agitation under continuous gas flow at 37°C. Control
experiments showed that cell viability as measured by trypan
blue exclusion was essentially unaffected by this treatment.
Cells were harvested, washed extensively to remove unbound
pimonidazole and analysed by ELISA for covalently bound
pimonidazole and by the BCA reagent for protein content
according to instructions provided by Pierce Chemical.
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GE Arteel etal Jw
891
Perfusion ofrat livers
Female Sprague Dawley rats (120-130 g) were given stan-
dard laboratory chow and water ad libitum and then fasted
24 h before the beginning of the perfusion experiments. The
animals were anaesthetised with 50mg kg' intraperitoneal
sodium pentobarbitol and their livers (typical weight
3.5-4.0 g) were surgically isolated and perfused in the
anterograde direction at a 'normal' flow rate (4 ml min-' g l)
at 37°C with haemoglobin-free, Krebs-Henseleit bicarbonate
buffer, pH 7.4 (118 mM sodium chloride, 24.9 mM sodium
bicarbonate, 1.19 mM potassium dihydrogen phosphate,
1.18 mM magnesium sulphate, 4.74 mM potassium chloride
and 1.27 mm calcium chloride) saturated with 95% oxygen
and 5% carbon dioxide in a non-recirculating mode. After
20 min of perfusion at 4 ml min-' g-', livers were perfused in
either anterograde or retrograde directions for 50 min at low
flow rate (1 ml min-' g-') with Krebs-Henseleit buffer con-
taining 413 jiM pimonidazole hydrochloride. This concentra-
tion of pimonidazole was used in order to give a strong
binding signal during the short perfusion time. The duration
of the perfusion was chosen to be within the viability limits
of the model as determined previously by trypan blue uptake
and lactate dehydrogenase release (Bradford et al., 1986).
Following perfusion, one liver lobe was removed, flash-frozen
in liquid nitrogen and stored frozen for subsequent ELISA.
The remaining liver tissue was perfusion-fixed with 10%
formalin. A sample of fixed tissue was excised, embedded in
paraffin and sectioned at 6jim onto silanised, precoated glass
slides for immunohistochemical analysis. Control liver sam-
ples unlabelled with pimonidazole were also prepared.
Immunohistochemistry
Immunohistochemistry was carried out as described pre-
viously for CCI-103F (Cline et al., 1994). Sections of
formalin-fixed and paraffin-embedded liver tissue were
deparaffinised by treatment with xylene, a graded series of
alcohol and water mixtures and finally with water. Hydrated
tissue sections were treated briefly with 0.01% protease (pro-
nase E) in order to enhance antigen availability, washed and
exposed to mouse anti-pimonidazole IgG, MAb in PBS-
Tween for 2 h at 37°C. A second antibody comprising rat-
absorbed, horse anti-mouse antibody conjugated to perox-
idase was then applied to the tissue sections for 30 min.
Immunostaining of sublobular regions was achieved by
adding DAB peroxidase substrate to the sections followed by
incubation at 37°C for 20 min. The immunostained sections
were lightly counterstained with haematoxylin and mounted
with crystal mount solution.
Image analysis
An Image-1/AT image acquisition and analysis system
(Universal Imaging, Chester, PA, USA) incorporating an
Axioskop 50 microscope (Carl Zeiss, Thornwood, NY, USA)
was used to capture and analyse images of immunostained
tissue sections. Ten periportal and ten pericentral fields were
chosen randomly from each tissue section and positioned
such that respective vessel lumina were in the centre of each
field. Overall field-size dimensions were 190j.m x 190jim.
Colour detection thresholds were set for the red-brown col-
our of the DAB chromogen based on an intensely labelled
point and a default colour threshold width was determined.
The degree of labelling in each field was determined by the
percentage of the field area minus acellular space within the
default colour width as determined by the image analysis
system. This was an approach similar to that used for canine
tumours (Cline et al., 1994). For uniformity, comparison of
labelling was restricted to those lumina whose diameters fell
in the range 5-8jim. Results from each tissue section were
pooled to determine the means of area labelled in periportal
and pericentral regions.Binding of 2-nitroimWazoles to normal tissue
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Results
ELISA analysis
Except for pimonidazole, 2-nitroimidazoles were weak com-
petitors of solid phase antigens for pimonidazole antisera as
measured by ELISA. Cross-reactivity data for CCI-103F are
shown (Figure 1). Other 2-nitroimidazoles including mis-
onidazole, benznidazole and etanidazole showed little or no
cross-reactivity (data not shown). Enzyme-digested, pi-
monidazole-BSA adducts were approximately 25 times bet-
ter than free pimonidazole as competitive inhibitors of
antisera binding (Figure 1) but for convenience, pimon-
idazole was used as the standard. A correction factor of 25
was used to estimate the amount of pimonidazole bound to
cell and tissue protein. Because of the relative insensitivity of
the ELISA to free pimonidazole, analysis of tissue-bound
pimonidazole could be carried out without interference from
small amounts of free pimonidazole in tissue samples. Cel-
lular proteins labelled with pimonidazole were digested into
peptides before ELISA and it was assumed that adducts to
small molecules such as glutathione were detected with the
same sensitivity as protein adducts.
Oxygen dependence ofpimonidazole binding in EMT6 cells
The oxygen dependence of pimonidazole binding to EMT6
cells in vitro showed half-maximal inhibition at a gas phase
oxygen concentration of 1500 p.p.m. or 0.15% (Figure 2).
Binding was measured by ELISA in terms of nmol
pimonidazole bound per g of protein in the cell suspensions.
The ratio of binding under anoxia (12 p.p.m. P02) to that
under air (2 x 105p.p.m. PO2) was 12:1 so that a wide
dynamic range was available for the binding experiments.
The concentration of oxygen that gave half-maximal inhibi-
tion of pimonidazole binding was similar to published values
of 0.1-0.3% for the half-maximal inhibition of misonidazole
binding (Franko et al., 1987). The protein content of the cell
suspensions was typically 1.75 mg ml-' and the concentration
of oxygen in the aqueous phase could be somewhat lower
than that in the gas phase owing to oxygen consumption
(Jones, 1985). The aqueous phase oxygen concentration was
not measured, however, and the Km for inhibition of
pimonidazole binding by oxygen must be considered to be
approximate. While measurement of the aqueous phase con-
centration of oxygen would provide a more accurate value
for the Ki,, the correspondence between pimonidazole and
Figure 3 Immunohistochemical analysis of pimonidazole binding in perfused liver (see Materials and methods). (a) The immuno-
staining pattern about the pericentral vein (PC) in a liver perfused in the anterograde direction (10 x 10). (b) The immunostaining
pattern about the portal triad (PP) for a liver perfused in the retrograde direction (10 x 10). (c) The single layer of immunostained
cells at the pericentral vein resulting from pimonidazole binding during retrograde perfusion (10 x 40). (d) Reveals the transition
from unstained cells to stained cells in the vicinity of the pericentral vein as a result of pimonidazole binding during anterograde
perfusion (10 x 100).Binding of 2-nitroimidazoles to normal tissue
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poses of the present experiment.
Intensity ofpimonidazole binding in liver tissue
The overall intensity of pimonidazole binding to tissue from
livers perfused at low flow rates when measured by ELISA of
homogenised, protease-digested tissue was not significantly
different in livers perfused in either anterograde (1.5 ± 0.8
nmol mg-' protein; n = 4) or retrograde (1.2 ± 0.3 nmol mg-'
protein; n = 3) directions. In this analysis, no distinction was
made between pimonidazole bound to small, acid-soluble
molecules and pimonidazole bound to large, acid-insoluble
molecules. It was found by UV analysis that digested
homogenates contained free pimonidazole in the range of
23-79 JLM. The tissue-bound values were corrected accord-
ingly.
Immunohistochemical patterns ofpimonidazole binding in liver
As expected, immunostaining in livers perfused at low flow
rates in the anterograde direction was localised in oxygen-
poor, centrilobular regions (Figure 3a). The pattern of
immunostaining was reversed in liver perfused in the retro-
grade direction; that is, the staining was now localised in the
oxygen-poor, periportal region of the tissue (Figure 3b).
The only exception to this reversal of immunostaining
when the oxygen gradient was reversed was the immunostain-
ing of the single layer ofcells directly adjacent to the pericen-
tral vein following retrograde perfusion (Figure 3c). No such
layer of immunostained cells was observed next to the
periportal area following perfusion in the anterograde direc-
tion.
At high magnification (x 1000, Figure 3d), immunostain-
ing increased from background levels to dense staining over
1-2 cell diameters. In lightly stained cells, the staining was
distributed equally over the nucleus and cytoplasm. In more
heavily stained cells, an intensified immunostaining was
observed over cell nuclei.
Image analysis ofimmunostained liver sections
Quantitative image analysis (Figure 4) revealed that the frac-
tion of liver tissue immunostained in the periportal regions
during perfusion in the retrograde direction was not
significantly different from that observed for the pericentral
regions during perfusion in the anterograde direction. The
single layer of immunostained cells around the central vein
did not contribute significantly to the fraction of tissue area
labelled during perfusion in the retrograde direction.
Discussion
The microregional patterns of 2-nitroimidazole binding
(Figure 3) are completely consistent with the distribution of
oxygen in liver perfused at low flow rates. There is no
evidence that specialised nitroreductase activity located in the
pericentral region of liver dominates the binding process as
Cobb et al. (1990a,b) suggested. The results presented here
indicate that oxygen-dependent nitroreductase activity is
homogenously distributed in liver so that 2-nitroimidazole
binding will occur whenever regional oxygen concentrations
decline to such a level that electrons flow to the nitro-
aromatic compounds rather than to oxygen. This conclusion
is in agreement with the known distribution of reducing
equivalents and nitroreductases in liver.
With respect to the distribution of reducing equivalents,
previous studies have shown that the potential for oxygen
uptake is similar in periportal and pericentral regions of liver
(Matsumura et al., 1986). That is, the high rate of oxygen
uptake in periportal regions during perfusion in the normal
or anterograde direction is shifted to the pericentral region
during perfusion in the retrograde direction. Importantly,
about 85% of oxygen consumption in liver tissue is due to
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Figure 4 Image analysis data (mean ± standard error of the
mean) for immunostained tissue sections following anterograde
(pericentral pimonidazole binding) and retrograde (primarily
periportal pimonidazole binding) perfusion (see Materials and
methods for details). The two bars to the left in the figure are the
area fractions labelled around the portal triad and the central
vein during perfusion in the anterograde direction. The two bars
to the right in the figure are the area fractions labelled around the
central vein and portal triad during perfusion in the retrograde
direction. Background immunostaining was negligible in the
absence of pimonidazole. Overall field size dimensions for the
analyses were 190 ltm x 190rim.
oxygen reduction by electrons from the electron transport
chain (Matsumura et al., 1986). These are the same electrons
that reduce nitroaromatic compounds in the absence of
oxygen so it is not surprising that the potential for nit-
roimidazole reduction and binding (Figure 3), like oxygen
uptake, is similar in pericentral and periportal regions of
liver.
With respect to the distribution of nitroreductases, it is
true that cytochrome P450-dependent nitroreductases are
localised predominantly in pericentral regions (Jungerman
and Katz, 1989), but other nitroreductases such as aldehyde
dehydrogenase (Wolpert et al., 1973) are distributed through-
out liver tissue (Kashiwagi et al., 1983). Enzyme distributions
are not altered during liver perfusion experiments (Thurman
and Kauffman, 1985) and it is unlikely that measurable
enzyme induction would occur during 50 min of low-flow
perfusion. Incubation under hypoxia for prolonged periods
(>8 h) is generally required to induce redox enzymes such as
DT-diaphorase (e.g. Phillips et al., 1994) and subsequent,
prolonged incubation under aerobic conditions is often
needed for the changes induced under hypoxia to be detec-
table (e.g. O'Dwyer et al., 1994). This appears to be the case
for liver tissue in vivo as well. For example, 8-9 days of
chronic in vivo hypoxia induced by inhalation of 10% oxygen
produced no detectable changes in rat hepatic cytochrome
P450 content (Aw et al., 1991).
If regional cytochrome P450-dependent nitroreductase
activity accounted for hypoxia marker binding in liver tissue
perfused in the anterograde direction, then perfusion in the
retrograde direction should leave the binding pattern
unchanged. That is, pimonidazole bioreduction would be
analogous to mono-oxygenation in phenobarbital-treated rats
which follows the distribution of cytochrome P450s irrespec-
tive of the direction of perfusion (Thurman and Kauffman,
1985). However, the pattern of pimonidazole binding follows
the distribution of oxygen in the tissue being completely
reversed after perfusion in the retrograde direction (Figure 3a
and b). Bioreductive activation of pimonidazole appears to
X_
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fall, therefore, into the class of processes such as oxygen
uptake for which underlying metabolic systems are available
uniformly throughout the liver. In support of this conclusion,
the extent of binding around the portal triad during retro-
grade perfusion is quantitatively similar to that around the
central vein during anterograde perfusion (Figure 4) and
overall binding intensities as measured by ELISA are not
significantly different for perfusion in either anterograde or
retrograde directions. It is clear that low oxygen concentra-
tion rather than unique nitroreductase activity determines the
distribution of 2-nitroimidazole binding in liver tissue.
Pimonidazole binding in the rim ofcells around the central
vein during perfusion in the retrograde direction is a minor
but interesting exception (Figure 3c). The single layer of cells
around the central vein is unique in other ways. For example,
these cells are the only cells in liver that possess the enzyme
glutamine synthetase (Gebhardt et al., 1988). This enzyme is
involved in ammonia detoxification and pH homeostasis
(Haussinger et al., 1986) but it would not appear to be
capable of reductively activating 2-nitroimidazole com-
pounds. It is possible that these cells possess unique nit-
roreductase activity in addition to specialised ammonia
metabolism although further work will be needed to confirm
this. In any case, the possibility that these cells or the mic-
roregional distribution of specialised nitroreductase activity
accounts for the predominant pattern of hypoxia marker
binding in liver is not supported by the present experiments.
It is known that intracellular uptake of weak bases such as
pimonidazole (pK, 8.6 at 37°C) can be influenced by changes
in extracellular pH. While normoxic liver has mechanisms for
pH homeostasis (Haussinger et al., 1986), acidosis can
accompany hypoxia/ischaemia in other tissues and it is ap-
propriate to consider the effect that changes in pH might
have on pimonidazole binding. For an extracellular pH of
7.3, pimonidazole concentration exceeds that in the sur-
rounding medium by a factor of 2-3 for both rodent and
human tumour cells (Dennis et al., 1985; Watts et al., 1990)
but as the extracellular pH declines to 6.6, intracellular
pimonidazole concentration falls to match that in the sur-
rounding medium (Dennis et al., 1985). This decrease in
intracellular concentration is accompanied by a parallel
decrease in the intensity of pimonidazole binding to cellular
glutathione and macromolecules. For example, a change in
extracellular pH from 7.3 to 6.8 leads to a decrease in the
concentration of glutathione and macromolecular adducts by
a factor of 2-3 (JM Yates et al., 1995, unpublished). A
decrease in extracellular pH in hypoxic regions could,
therefore, decrease pimonidazole binding. However, this
effect is small compared with the 12-fold difference in binding
intensity between anoxic and aerated cells (Figure 2) and,
with respect to the present experiments, in the wrong direc-
tion since binding was observed to increase, not decrease, in
the hypoxic regions ofperfused liver. In the image analysis of
hypoxia marker binding (Figure 4) it should be noted that,
once the threshold intensity distinguishing stained from uns-
tained cells is established, small differences in the intensity of
pimonidazole binding among cells in the immunostained
regions are not registered. The ELISA data do reflect inten-
sity differences but, in fact, they revealed no significant
difference in binding intensity between pericentral and
periportal regions. Therefore, we conclude that changes in
pH did not play a role in pimonidazole binding patterns
observed in the perfused liver experiments.
Hypoxia markers do not provide a precise measure of
oxygen concentration in tissues but it is reasonable to
assume, based on comparison with misonidazole, that half-
maximal inhibition of pimonidazole binding in vivo occurs in
the range of 1-6tM oxygen (Franko and Koch, 1984).
While this concentration range is well below the values
measured in normal tissues with oxygen electrodes, the pres-
ent results show that oxygen gradients are created on a
cellular scale (Figure 3d) so that average tissue P02 is not a
good predictor of 2-nitroimidazole binding under normoxic
conditions.
Hypoxia markers were developed primarily for use in
tumours where the patterns ofbinding have been found to be
consistent with the distributions of oxygen expected on the
basis of the Thomlinson and Gray (1955) analysis of car-
cinomas of the human bronchus. Nevertheless, the hypoxia
marker technique is dependent on nitroreductase activity in
tissues and there is little control of this aspect of the assay -
particularly in a clinical setting. The challenge posed by the
observation that 2-nitroimidazoles bind to some normoxic
tissues cannot, therefore, be ignored. It raises the mechanistic
question of whether binding in all cases is due to low oxygen
concentration and the practical question of whether normal
tissue hypoxia will interfere with the use of hypoxia markers
in tumours. From a mechanistic point of view, the demon-
stration that the binding of 2-nitroimidazoles in liver tissue is
primarily dependent on oxygen concentration provides sup-
port for the idea that hypoxia markers, in general, reflect
patterns of oxygen concentrations in normal and tumour
tissue. From a practical point of view, this opens up the
possibility that hypoxia markers will be useful in studies of
liver pathophysiology associated with changes in liver
oxygenation as appears to be the case for alcohol-induced
liver damage (Thurman et al., 1986; Arteel et al., 1995).
Hypoxia markers might also be used in identifying normal
tissues at risk with respect to hypoxia-dependent cytotoxins
or to radiation sensitisation by procedures designed to inc-
rease tissue P02* Carbogen breathing, for example, increases
radiation sensitivity in skin (Rojas et al., 1992) as hypoxia
marker binding would predict. Finally, the results of the
present study support the premise underlying the develop-
ment of the immunohistochemical, hypoxia marker method.
Non-invasive hypoxia marker techniques might be useful in
following changes in tumour hypoxia, but a biopsy-based,
histological investigation of tumour hypoxia is the only way
to discriminate between hypoxia in tumour and surrounding
normal tissue (Raleigh et al., 1987).
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